Virote Sriuranpong

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 772 citations

Radiology, Medicine, Bronchial Neoplasm +9

Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis

Krisanee Chalitchagorn, Shanop Shuangshoti, Nusara Hourpai et al. · Oncogene · 2004 · 411 citations

Normal Tissues, Oncogenic Agent, Epigenetic Change +9

Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.

Virote Sriuranpong, Jong‐In Park, Panomwat Amornphimoltham et al. · PubMed · 2003 · 274 citations

Stat3 Deregulation, Interleukin 6/Gp130, Immunology +19